TPR
TPR (Nucleoprotein TPR) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Medulloblastoma.
Overview
Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope. Functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs, plays a role in the establishment of nuclear-peripheral chromatin compartmentalisation in interphase, and in the mitotic spindle checkpoint signalling during mitosis. Involved in the quality control and retention of unspliced mRNAs in the nucleus; in association with NUP153, regulates the nuclear export of unspliced mRNA species bearing constitutive transport element (CTE) in a NXF1- and KHDRBS1-independent manner.
Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.93, affected pathway 0.76, genetic association 0.04, somatic mutation 0.80). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Hepatocellular Carcinoma, Medulloblastoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TPR (Nucleoprotein TPR) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Medulloblastoma.
- 1 · What it is
TPR (Nucleoprotein TPR) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Hepatocellular carcinoma and Medulloblastoma.
- 2 · What goes wrong in cancer
Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope.
- 3 · How drugs use it
No product in this corpus aims at TPR yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:12017 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P12270 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000047410 (association with cancer (MONDO_0004992) 0.71; (GraphQL API, CC0)); IntOGen TPR (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope. Functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs, plays a role in the establishment of nuclear-peripheral chromatin compartmentalisation in interphase, and in the mitotic spindle checkpoint signalling during mitosis. Involved in the quality control and retention of unspliced mRNAs in the nucleus; in association with NUP153, regulates the nuclear export of unspliced mRNA species bearing constitutive transport element (CTE) in a NXF1- and KHDRBS1-independent manner. Negatively regulates both the association of CTE-containing mRNA with large polyribosomes and translation initiation. Does not play any role in Rev response element (RRE)-mediated export of unspliced mRNAs. Implicated in nuclear export of mRNAs transcribed from heat shock gene promoters; associates both with chromatin in the HSP70 promoter and with mRNAs transcribed from this promoter under stress-induced conditions. Location: Nucleus; Nucleus membrane; Nucleus envelope; Nucleus, nuclear pore complex (UniProt). Locus 1q31.1 (HGNC).
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Medulloblastoma: IntOGen driver in 1 cohort (MBL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TPR" OR ABSTRACT:"TPR" OR TITLE:"translocated promoter region, nuclear basket protein" OR ABSTRACT:"translocated promoter region, nuclear basket protein" OR TITLE:"Nucleoprotein TPR" OR ABSTRACT:"Nucleoprotein TPR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TPR, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCCAR1
Shares Medulloblastoma, IntOGen.
- TargetCHD7
Shares Medulloblastoma, IntOGen.
- TargetZNF274
Shares Medulloblastoma, IntOGen.
- TargetELP1
Shares Medulloblastoma, Open Targets Platform.
- TargetGPR161
Shares Medulloblastoma, Open Targets Platform.
- TargetWAS
Shares Medulloblastoma, IntOGen, Open Targets Platform.
- TargetTRIM33
Shares Medulloblastoma, IntOGen, Open Targets Platform.
- TargetFOXO3
Shares Medulloblastoma, IntOGen, Open Targets Platform.